Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Gambacorti-Passerini

Showing results (1-10 of 205) with videos related to

Pageof 21
Sort By:
Frontiers in Bioscience (Elite Edition)|December 29, 2015
ALK inhibitors for clinical use in cancer therapyFrancesca Farina, Carlo Gambacorti-Passerini
Leukemia & Lymphoma|December 25, 2003
ALK a novel lymphoma-associated tumor antigen for vaccination strategiesLorena Passoni, Carlo Gambacorti-Passerini
American Journal of Hematology|November 6, 2014
How I treat newly diagnosed chronic myeloid leukemia in 2015Carlo Gambacorti-Passerini, Rocco Piazza
European Journal of Cancer (Oxford, England : 1990)|April 20, 2010
Bosutinib: a review of preclinical studies in chronic myelogenous leukaemiaFrank Boschelli, Kim Arndt, Carlo Gambacorti-Passerini
Frontiers in Oncology|December 3, 2021
Molecular Pathogenesis of <i>BCR-ABL</i>-Negative Atypical Chronic Myeloid LeukemiaDiletta Fontana, Carlo Gambacorti-Passerini, Rocco Piazza
Molecular & Cellular Oncology|April 16, 2021
Impact of <i>ETNK1</i> somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damageDiletta Fontana, Carlo Gambacorti-Passerini, Rocco Piazza
Future Oncology (London, England)|December 14, 2019
The role of bosutinib in the treatment of chronic myeloid leukemiaCarlo Gambacorti-Passerini, Philipp le Coutre, Rocco Piazza
Current Topics in Medicinal Chemistry|April 26, 2011
The ALK gene, an attractive target for inhibitor developmentCarmen J Tartari, Leonardo Scapozza, Carlo Gambacorti-Passerini
American Journal of Hematology|November 21, 2015
Chronic myeloid leukemia: Second-line drugs of choiceCarlo Gambacorti-Passerini, Andrea Aroldi, Nicoletta Cordani, et al.
Cancer Medicine|March 3, 2015
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALKDiletta Fontana, Monica Ceccon, Carlo Gambacorti-Passerini, et al.
Pageof 21

Showing results (1-10 of 205) with videos related to

Sort By:
Pageof 21
Frontiers in Bioscience (Elite Edition)|December 29, 2015
ALK inhibitors for clinical use in cancer therapyFrancesca Farina, Carlo Gambacorti-Passerini
Leukemia & Lymphoma|December 25, 2003
ALK a novel lymphoma-associated tumor antigen for vaccination strategiesLorena Passoni, Carlo Gambacorti-Passerini
American Journal of Hematology|November 6, 2014
How I treat newly diagnosed chronic myeloid leukemia in 2015Carlo Gambacorti-Passerini, Rocco Piazza
European Journal of Cancer (Oxford, England : 1990)|April 20, 2010
Bosutinib: a review of preclinical studies in chronic myelogenous leukaemiaFrank Boschelli, Kim Arndt, Carlo Gambacorti-Passerini
Frontiers in Oncology|December 3, 2021
Molecular Pathogenesis of <i>BCR-ABL</i>-Negative Atypical Chronic Myeloid LeukemiaDiletta Fontana, Carlo Gambacorti-Passerini, Rocco Piazza
Molecular & Cellular Oncology|April 16, 2021
Impact of <i>ETNK1</i> somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damageDiletta Fontana, Carlo Gambacorti-Passerini, Rocco Piazza
Future Oncology (London, England)|December 14, 2019
The role of bosutinib in the treatment of chronic myeloid leukemiaCarlo Gambacorti-Passerini, Philipp le Coutre, Rocco Piazza
Current Topics in Medicinal Chemistry|April 26, 2011
The ALK gene, an attractive target for inhibitor developmentCarmen J Tartari, Leonardo Scapozza, Carlo Gambacorti-Passerini
American Journal of Hematology|November 21, 2015
Chronic myeloid leukemia: Second-line drugs of choiceCarlo Gambacorti-Passerini, Andrea Aroldi, Nicoletta Cordani, et al.
Cancer Medicine|March 3, 2015
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALKDiletta Fontana, Monica Ceccon, Carlo Gambacorti-Passerini, et al.
Pageof 21